Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Biologics Naming Plan: Industry Wants 'Memorable' Suffixes

Executive Summary

Random letter-based suffixes will make it difficult for prescribers and patients to identify a given product, biopharma companies say, requesting that suffixes be derived from the license-holder's name; GPhA, Federal Trade Commission say FDA plan for distinguishable names will create confusion and uncertainty.

Advertisement

Related Content

Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel